Pelage Pharmaceuticals, a clinical-stage regenerative medicine company based in Los Angeles, has raised $120 million in Series B financing to accelerate development of its lead hair restoration therapy, PP405. The round was co-led by ARCH Venture Partners and GV (formerly Google Ventures), with participation from existing backers Main Street Advisors, Visionary Ventures, and YK Bioventures.
PP405 is a topical small molecule designed to reactivate dormant hair follicle stem cells, offering a potential first-in-class solution for both men and women experiencing hair loss. The therapy is currently in Phase 2a clinical trials and represents a novel, non-invasive approach to restoring natural hair growth by targeting the body's regenerative potential.
The financing will support continued clinical advancement of PP405, which is based on breakthrough research in stem cell biology and metabolism. Unlike many competitors focusing on cell therapy or transplant-based interventions, Pelage's small-molecule approach seeks to stimulate the body's own regenerative machinery, which could simplify treatment delivery and broaden patient access.
As part of the financing, Cathy Friedman, Executive Venture Partner at GV who led Pelage's Series A round, has been appointed Chair of the Board. Richard Heyman, Ph.D., Venture Partner at ARCH Venture Partners, will also join the board, alongside CEO Daniel Gil, Ph.D., and co-founder William Lowry, Ph.D. The strengthened board underscores investor confidence in Pelage's scientific foundation and commercial potential.
Pelage's CEO, Daniel Gil, Ph.D., is a veteran scientist and biotech leader who previously held senior scientific roles at Amgen and Regeneron Pharmaceuticals, where he led discovery programs in stem cell signaling and tissue regeneration. He has steered the company from early preclinical discovery through human trials, cultivating a multidisciplinary team that merges academic research with commercial drug development.
The hair restoration market is projected to exceed $10 billion globally by 2030, according to industry analysts. Pelage joins a growing field of biotechnology companies pursuing regenerative approaches, including Stemson Therapeutics and Allergan's regenerative dermatology initiatives. If successful, PP405 could redefine the landscape of hair restoration and mark a significant step forward in translating stem cell science into practical medicine.
For more information, visit the original announcement at citybiz.
